The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Measurable residual disease (MRD) refers to neoplastic cells that cannot be detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia (AML), determining the association of MRD with survival may improve prognostication and inform selection of efficient clinical trial end points. OBJECTIVE: To examine the association between MRD status and disease-free survival (DFS) and overall survival (OS) in patients with AML using scientific literature. DATA SOURCES: Clinical studies on AML published between January 1, 2000, and October 1, 2018, were identified via searches of PubMed, Embase, and MEDLINE. STUDY SELECTION: Literature search and study screening were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Studies that assessed DFS or OS by MRD status in patients with AML were included. Reviews, non-English-language articles, and studies reporting only outcomes after hematopoietic cell transplantation or those with insufficient description of MRD information were excluded. DATA EXTRACTION AND SYNTHESIS: Study sample size, median patient age, median follow-up time, MRD detection method, MRD assessment time points, AML subtype, specimen source, and survival outcomes were extracted. Meta-analyses were performed separately for DFS and OS using bayesian hierarchical modeling. MAIN OUTCOMES AND MEASURES: Meta-analyses of survival probabilities and hazard ratios (HRs) were conducted for OS and DFS according to MRD status. RESULTS: Eighty-one publications reporting on 11 151 patients were included. The average HR for achieving MRD negativity was 0.36 (95% bayesian credible interval [CrI], 0.33-0.39) for OS and 0.37 (95% CrI, 0.34-0.40) for DFS. The estimated 5-year DFS was 64% for patients without MRD and 25% for those with MRD, and the estimated OS was 68% for patients without MRD and 34% for those with MRD. The association of MRD negativity with DFS and OS was significant for all subgroups, with the exception of MRD assessed by cytogenetics or fluorescent in situ hybridization. CONCLUSIONS AND RELEVANCE: The findings of this meta-analysis suggest that achievement of MRD negativity is associated with superior DFS and OS in patients with AML. The value of MRD negativity appears to be consistent across age groups, AML subtypes, time of MRD assessment, specimen source, and MRD detection methods. These results support MRD status as an end point that may allow for accelerated evaluation of novel therapies in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Gelman, A., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2003) · doi:10.1201/9780429258480 · Cited by 27,276
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×
“1; Bormisoft) to extract coordinates of points on the curves and applied a numeric algorithm to reconstruct survival data for each MRD group29; (2) when Kaplan-Meier curves were not available, we used reported hazard ratios (HRs) and their 95% CIs; and (3) for articles that only provided survival proportions at fixed…”
MethodDöhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Guyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
(2010) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2010.01108.x · Cited by 1,443
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationRoyston, P., & Parmar, M. K. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-152 · Cited by 1,062
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationGökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H.-A., et al. (2018) · Blood · doi:10.1182/blood-2017-08-798322 · Cited by 858
Assessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
Self-citationMoving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Uno, H., Claggett, B., Tian, L., Inoue, E., Gallo, P., Miyata, T., Schrag, D., Takeuchi, M., Uyama, Y., Zhao, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2208 · Cited by 810
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Self-citationBerry, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1927 · Cited by 726
Self-citationBerry, D. A., Zhou, S., Higley, H., Mukundan, L., Fu, S., Reaman, G. H., Wood, B. L., Kelloff, G. J., Jessup, J. M., & Radich, J. P. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0580 · Cited by 599
Self-citationBrüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2708 · Cited by 537
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Cilloni, D., Renneville, A., Hermitte, F., Hills, R. K., Daly, S., Jovanovic, J. V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4865 · Cited by 445
Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
Hourigan, C. S., Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03011 · Cited by 442
Self-citationBassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Yin, J. A. L., O'Brien, M. A., Hills, R. K., Daly, S. B., Wheatley, K., & Burnett, A. K. (2012) · Blood · doi:10.1182/blood-2012-06-435669 · Cited by 425
Krönke, J., Schlenk, R. F., Jensen, K.-O., Tschürtz, F., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0371 · Cited by 399
Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.-M., Knoth, H., Röllig, C., Schetelig, J., et al. (2012) · Leukemia · doi:10.1038/leu.2011.234 · Cited by 389
Jourdan, E., Boissel, N., Chevret, S., Delabesse, E., Renneville, A., Cornillet, P., Blanchet, O., Cayuela, J.-M., Recher, C., Raffoux, E., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462879 · Cited by 363
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 345
Klco, J. M., Miller, C. A., Griffith, M., Petti, A., Spencer, D. H., Ketkar-Kulkarni, S., Wartman, L. D., Christopher, M., Lamprecht, T. L., Helton, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.9643 · Cited by 339
San Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
Zhu, H.-H., Zhang, X.-H., Qin, Y.-Z., Liu, D.-H., Jiang, H., Chen, H., Jiang, Q., Xu, L.-P., Lu, J., Han, W., et al. (2013) · Blood · doi:10.1182/blood-2012-11-468348 · Cited by 327
Self-citationFreeman, S. D., Virgo, P., Couzens, S., Grimwade, D., Russell, N., Hills, R. K., & Burnett, A. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1753 · Cited by 317
Self-citationBalsat, M., Renneville, A., Thomas, X., de Botton, S., Caillot, D., Marceau, A., Lemasle, E., Marolleau, J.-P., Nibourel, O., Berthon, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1875 · Cited by 303
Loken, M. R., Alonzo, T. A., Pardo, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ho, P. A., Franklin, J., Cooper, T. M., Gamis, A. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408336 · Cited by 297
Buckley, S. A., Wood, B. L., Othus, M., Hourigan, C. S., Ustun, C., Linden, M. A., DeFor, T. E., Malagola, M., Anthias, C., Valkova, V., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159343 · Cited by 283
Self-citationChen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Self-citationTrinquart, L., Jacot, J., Conner, S. C., & Porcher, R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2488 · Cited by 251
Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
Inaba, H., Coustan-Smith, E., Cao, X., Pounds, S. B., Shurtleff, S. A., Wang, K. Y., Raimondi, S. C., Onciu, M., Jacobsen, J., Ribeiro, R. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5323 · Cited by 217
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A. P., Snel, A. N., Scholten, W. J., Pabst, T., Verhoef, G., Löwenberg, B., Zweegman, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107587 · Cited by 215
Pui, C.-H., Pei, D., Coustan-Smith, E., Jeha, S., Cheng, C., Bowman, W. P., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Inaba, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70082-3 · Cited by 207
Freeman, S. D., Hills, R. K., Virgo, P., Khan, N., Couzens, S., Dillon, R., Gilkes, A., Upton, L., Nielsen, O. J., Cavenagh, J. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.3425 · Cited by 201
Self-citationShayegi, N., Kramer, M., Bornhäuser, M., Schaich, M., Schetelig, J., Platzbecker, U., Röllig, C., Heiderich, C., Landt, O., Ehninger, G., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461749 · Cited by 196
Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403405 · Cited by 184
Minimal residual disease in acute myeloid leukaemia
Hourigan, C. S., & Karp, J. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.100 · Cited by 180
Self-citationClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6757 · Cited by 180
Self-citationLapillonne, H., Renneville, A., Auvrignon, A., Flamant, C., Blaise, A., Perot, C., Lai, J.-L., Ballerini, P., Mazingue, F., Fasola, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5303 · Cited by 164
Perea, G., Lasa, A., Aventín, A., Domingo, A., Villamor, N., Paz Queipo de Llano, M., Llorente, A., Juncà, J., Palacios, C., Fernández, C., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404015 · Cited by 161
Langebrake, C., Creutzig, U., Dworzak, M. N., Hrušák, O., Mejstříková, E., Griesinger, F., Zimmermann, M., & Reinhardt, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4312 · Cited by 156
van der Velden, V. H. J., van der Sluijs‐Gelling, A. J., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., Wheatley, K., Bierings, M., Schuurhuis, G. J., de Graaf, S. S. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.153 · Cited by 143
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
Coustan‐Smith, E., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Pui, C., Pounds, S. B., Andreánsky, M., Behm, F. G., Raimondi, S. C., Shurtleff, S. A., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04610.x · Cited by 142
Prognostic Impact of Minimal Residual Disease in CBFB-MYH11 –Positive Acute Myeloid Leukemia
Corbacioglu, A., Scholl, C., Schlenk, R. F., Eiwen, K., Du, J., Bullinger, L., Fröhling, S., Reimer, P., Rummel, M., Derigs, H. G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6468 · Cited by 139
Buccisano, F., Maurillo, L., Spagnoli, A., Principe, M. I. D., Fraboni, D., Panetta, P., Ottone, T., Consalvo, M. I., Lavorgna, S., Bulian, P., et al. (2010) · Blood · doi:10.1182/blood-2009-12-258178 · Cited by 136
Monitoring of minimal residual disease in acute myeloid leukemia
Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2007) · Cancer · doi:10.1002/cncr.23128 · Cited by 112
Hubmann, M., Köhnke, T., Hoster, E., Schneider, S. E., Dufour, A., Zellmeier, E., Fiegl, M., Braess, J., Bohlander, S. K., Subklewe, M. S., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.104133 · Cited by 96
Maurillo, L., Buccisano, F., Spagnoli, A., Poeta, G. D., Panetta, P., Neri, B., Principe, M. I. D., Mazzone, C., Consalvo, M. I., Tamburini, A., et al. (2007) · Haematologica · doi:10.3324/haematol.10432 · Cited by 93
Lambert, J., Lambert, J., Nibourel, O., Pautas, C., Hayette, S., Cayuela, J., Terré, C., Rousselot, P. H., Dombret, H., Chevret, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2196 · Cited by 90
Tierens, A. M., Björklund, E., Siitonen, S. M., Marquart, H. V., Jürgensen, G. W., Pelliniemi, T., Forestier, E., Hasle, H., Jahnukainen, K., Lausen, B., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14093 · Cited by 89
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 86
Self-citationOthus, M. K. D., Wood, B. L., Stirewalt, D. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.120 · Cited by 80
Weisser, M., Kern, W., Schoch, C., Hiddemann, W., Haferlach, T., & Schnittger, S. (2005) · PubMed · Cited by 79
Sockel, K., Wermke, M., Radke, J., Kiani, A., Schaich, M. A., Bornhäuser, M., Ehninger, G., Thiede, C., & Platzbecker, U. (2011) · Haematologica · doi:10.3324/haematol.2011.044388 · Cited by 73
Kim, Y., Lee, G. D., Park, J. K., Yoon, J.-H., Kim, H.-J., Min, W.-S., & Kim, M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.61 · Cited by 73
Köhnke, T., Sauter, D., Ringel, K., Hoster, E., Laubender, R. P., Hubmann, M., Bohlander, S. K., Kakadia, P. M., Schneider, S., Dufour, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.186 · Cited by 65
Chen, Y., Cortes, J. E., Estrov, Z. E., Faderl, S. H., Qiao, W., Abruzzo, L. V., Garcia‐Manero, G., Pierce, S. A., Huang, X., Kebriaei, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2873 · Cited by 65
Self-citationShort, N. J., & Ravandi, F. (2019) · Haematologica · doi:10.3324/haematol.2018.208454 · Cited by 52
Self-citationOnecha, E., Linares, M., Rapado, I., Ruiz‐Heredia, Y., Martínez‐Sánchez, P., Cedena, M., Pratcorona, M., de Oteyza, J. P., Herrera, P., Barragán, E., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194712 · Cited by 50
Hoyos, M., Nomdedeu, J. F., Esteve, J., Duarte, R. F., Ribera, J., Llorente, A., Escoda, L., Bueno, J., Tormo, M., Gallardo, D., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12130 · Cited by 48
Weber, S., Alpermann, T., Dicker, F., Jeromin, S., Nadarajah, N., Eder, C., Fasan, A., Kohlmann, A., Meggendorfer, M., Haferlach, C., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.71 · Cited by 47
Parkin, B. L., Londoño-Joshi, A. I., Kang, Q., Tewari, M., Rhim, A. D., & Malek, S. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91964 · Cited by 47
Ferret, Y., Boissel, N., Hélevaut, N., Madic, J., Nibourel, O., Marceau‐Renaut, A., Bucci, M., Geffroy, S., Celli‐Lebras, K., Castaigné, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183525 · Cited by 47
Boddu, P. C., Jorgensen, J. L., Kantarjian, H. M., Borthakur, G. M., Kadia, T. M., Daver, N. G., Alvarado, Y., Pemmaraju, N., Bose, P., Naqvi, K., et al. (2017) · Leukemia · doi:10.1038/leu.2017.285 · Cited by 46
Self-citationPigazzi, M., Manara, E., Buldini, B., Beqiri, V., Bisio, V., Tregnago, C., Rondelli, R., Masetti, R., Putti, M. C., Fagioli, F., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.114579 · Cited by 45
Chou, W., Hou, H., Liu, C., Chen, C., Lin, L., Huang, Y.-C., Chao, Y.-S., Hsu, C.-A., Huang, C., & Tien, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq402 · Cited by 40
Malagola, M., Skert, C., Borlenghi, E., Chiarini, M., Cattaneo, C. M., Morello, E., Cancelli, V., Cattina, F., Cerqui, E., Pagani, C., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.593 · Cited by 34
Höllein, A., Jeromin, S., Meggendorfer, M., Fasan, A., Nadarajah, N., Kern, W., Haferlach, C., & Haferlach, T. (2018) · Leukemia · doi:10.1038/s41375-018-0086-0 · Cited by 28
Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia
Zhang, L., Cao, Z., Ruan, M., Zeng, Q., Zhao, L., Li, Q., Zou, Y., Wang, J., & Zhu, X. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25109 · Cited by 22
Weber, S., Haferlach, T., Alpermann, T., Perglerová, K., Schnittger, S., Haferlach, C., & Kern, W. (2016) · British Journal of Haematology · doi:10.1111/bjh.14343 · Cited by 16
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Self-citationHeuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Self-citation
Metadata
- Authors
- Short, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., Qi, X., Kantarjian, H., & Ravandi, F.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1890
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3092079205
- Cited by
- 390
- References
- 86
- FWCI
- 25.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.